{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0047833\nAge: 77\nGender: Male\nSample ID: P-0047833-T02-IM6\nGene Panel: IMPACT468\nCancer Type: Prostate Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 40.0%\n=============\nDNA Variants:\nSOCS1 c.80C>G (p.S27C) - in 17.00% of 456 reads\nCNA Data:\nMEN1 - High Level Amplification\nCCND1 - High Level Amplification\nALK - Homozygous Deletion\nFOXO1 - Homozygous Deletion\nPLCG2 - Homozygous Deletion\nCYSLTR2 - Homozygous Deletion\nFLT4 - Homozygous Deletion\nRPS6KB2 - High Level Amplification\nRB1 - Homozygous Deletion\nCRLF2 - Homozygous Deletion\nBRCA2 - Homozygous Deletion\nTP53 - Homozygous Deletion\nALOX12B - Homozygous Deletion\nAURKB - Homozygous Deletion\nFGF4 - High Level Amplification\nFGF3 - High Level Amplification\nFGF19 - High Level Amplification\nDUSP4 - Homozygous Deletion\nNKX3-1 - Homozygous Deletion\nStructural Variants:\nAR - nan (DELETION)\nLRBA - BRAF (nan)\nLRBA - BRAF (TRANSLOCATION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Prostate Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Androgen Receptor Signaling Inhibitors (e.g., Enzalutamide, Abiraterone)\",\n    \"Prior Treatment or Resistance Status\": \"Not specified\",\n    \"Genomic Features\": \"AR deletion, BRAF translocation\",\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/enzalutamide and https://www.fda.gov/drugs/resources-information-approved-drugs/abiraterone\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Prostate Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"PARP Inhibitors (e.g., Olaparib, Rucaparib)\",\n    \"Prior Treatment or Resistance Status\": \"BRCA2 homozygous deletion\",\n    \"Genomic Features\": \"BRCA2 homozygous deletion\",\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/olaparib and https://www.fda.gov/drugs/resources-information-approved-drugs/rucaparib\"\n  },\n  \"Treatment 3\": {\n    \"Disease Name\": \"Prostate Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Targeted Therapy for Amplifications (e.g., FGFR inhibitors like Erdafitinib)\",\n    \"Prior Treatment or Resistance Status\": \"FGF4, FGF3, FGF19 high-level amplifications\",\n    \"Genomic Features\": \"FGF4, FGF3, FGF19 high-level amplifications\",\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/erdafitinib\"\n  },\n  \"Treatment 4\": {\n    \"Disease Name\": \"Prostate Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"CDK4/6 Inhibitors (e.g., Palbociclib)\",\n    \"Prior Treatment or Resistance Status\": \"CCND1 high-level amplification\",\n    \"Genomic Features\": \"CCND1 high-level amplification\",\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib\"\n  }\n}"
}